Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PF 03814735

Known as: Aurora Kinase Inhibitor PF-03814735, PF-03814735, PF03814735 
An aurora kinase inhibitor with potential antineoplastic activity. PF-03814735 binds to and inhibits aurora kinases, serine-threonine kinases that… Expand
National Institutes of Health

Related topics

Related topics

1 relation
Aurora Kinase A

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor.
Thyroid cancer (TC) is a very common malignancy worldwide. Chief among the innovative molecular drug targets for TC are… Expand
2019
2019
Characterization of in vitro metabolism of focal adhesion kinase inhibitors by LC/MS/MS
HighlightsThe in vitro metabolites of FAK inhibitors were analyzed by LC/MS/MS.The structures and fragmentation patterns were… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2015
Review
2015
Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors.
Aurora kinase A, B and C, are key regulators of mitosis and are over expressed in many of the human cancers, making them an ideal… Expand
2013
2013
An exploration of pathways involved in lung carcinoid progression using gene expression profiling.
Pulmonary carcinoids comprise a well-differentiated subset of neuroendocrine tumors usually associated with a favorable prognosis… Expand
  • table II
  • table II
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2012
Highly Cited
2012
An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
PF-03814735 is a novel, reversible inhibitor of Aurora kinases A and B that finished a phase I clinical trial for the treatment… Expand
  • table 1
2011
2011
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
This phase I study (ClinicalTrials.gov ID: NCT00424632) evaluated the safe dose, pharmacokinetics, and pharmacodynamics of the… Expand
Highly Cited
2010
Highly Cited
2010
PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy
The Aurora family of highly related serine/threonine kinases plays a key role in the regulation of mitosis. Aurora1 and Aurora2… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2008
2008
Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: Preliminary results
2517 Background: Aurora kinases are a family of kinases that play a crucial role in regulating segregation of chromosomes and… Expand
2008
2008
282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced…
 
2008
2008
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE